SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-22-015744
Filing Date
2022-08-09
Accepted
2022-08-09 07:15:30
Documents
14
Period of Report
2022-08-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K cogt-20220809.htm   iXBRL 8-K 77470
2 EX-99.1 cogt-ex99_1.htm EX-99.1 170477
3 GRAPHIC img214414700_0.jpg GRAPHIC 78289
  Complete submission text file 0000950170-22-015744.txt   489768

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cogt-20220809_lab.xml EX-101.LAB 14076
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cogt-20220809.xsd EX-101.SCH 2467
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cogt-20220809_pre.xml EX-101.PRE 11374
8 EXTRACTED XBRL INSTANCE DOCUMENT cogt-20220809_htm.xml XML 4886
Mailing Address 200 CAMBRIDGE PARK DRIVE SUITE 3100 CAMBRIDGE MA 02140
Business Address 200 CAMBRIDGE PARK DRIVE SUITE 3100 CAMBRIDGE MA 02140 617-945-5576
Cogent Biosciences, Inc. (Filer) CIK: 0001622229 (see all company filings)

IRS No.: 465308248 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38443 | Film No.: 221146375
SIC: 2834 Pharmaceutical Preparations